September 15, 2014
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Herantis Pharma pursues phase 2 study for dry eye treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
The U.S. Food and Drug Administration has cleared the Investigational New Drug application of Herantis Pharma for a phase 2 clinical study of Cis-UCA eye drops for dry eye syndrome.
According to a press release from Herantis, patient enrollment is planned to begin by the end of this year.
Ora Inc. will run the phase 2 clinical study at three investigational sites in the U.S.
The study will enroll a total of 150 patients randomized in three treatment groups receiving either a placebo or one of two different doses of Cis-UCA eye drops, utilizing Ora’s Controlled Adverse Environment dry eye system, according to the press release.